Public health plans should cover Mounjaro for type 2 diabetes, Canada’s Drug Agency recommends

Canada’s Drug Agency issued a generally positive draft recommendation for Eli Lilly’s Mounjaro, saying public plans should cover tirzepatide for type 2 diabetes if Lilly offers a discount. At low doses, the agency says Mounjaro should be reimbursed no more than Ozempic; at higher doses, it recommends a 25% to 49% discount off list price. The report estimates public coverage could cost $1.97 billion over three years, while Lilly is still seeking coverage for related drug Zepbound in two indications.

Analysis

The real signal here is not incremental access to one GLP-1, but that Canadian public payers are moving toward a reference-pricing framework that anchors tirzepatide against semaglutide rather than on a standalone premium. That compresses Lilly’s pricing latitude in Canada and makes volume growth contingent on conceding margin, which is a useful read-through for other single-payer markets that often follow a similar cost-effectiveness script. The bigger second-order effect is on payer mix: if Mounjaro gains coverage, it likely expands class adoption but also accelerates substitution pressure away from higher-margin, self-pay channels.

Near term, the equity risk is less about absolute Canadian revenue and more about the signaling effect on global negotiations. Lilly has been able to monetize convenience and perceived efficacy at a premium; a public rebasing against Ozempic weakens that narrative and may stiffen buyer resistance in Europe and parts of Asia over the next 1-2 quarters. Novo benefits tactically because the bar for defending semaglutide pricing is now lower if tirzepatide is forced into discount bands in another major developed market.

The contrarian angle is that the market may be underestimating how much this helps total GLP-1 penetration. If provincial coverage unlocks a population that has been constrained by out-of-pocket cost, the volume uplift can partially offset price cuts, especially if patients persist longer on therapy. The bigger swing factor is not this decision itself but the coming generic semaglutide review: once that hits, the benchmark price resets downward and could force a second, more meaningful round of renegotiation on tirzepatide within 6-12 months.

Key Decisions for Investors

• Short-term: fade any knee-jerk strength in LLY on the headline; use 1-3 month horizons to buy downside via LLY puts or put spreads if implied vol remains below event-risk norms. Thesis: Canada is small, but the pricing precedent is negative for global negotiating leverage.
• Relative value: long NVO / short LLY over the next 1-2 quarters. If Canadian and other ex-US payers use semaglutide as the reference point, Lilly’s premium expansion story is harder to sustain while Novo’s broader installed base should preserve negotiating power.
• Optionality trade: buy longer-dated calls on biotech/service names that benefit from broader GLP-1 access and persistence, rather than pure manufacturers. The cleaner expression is a basket of obesity-care enablers versus direct drug exposure if coverage expands but pricing compresses.
• Monitor for a 6-12 month catalyst around generic semaglutide approval in Canada; if that progresses, add to LLY underweight on the expectation of a second-stage price reset. Risk to the short: Lilly can offset some pricing pressure with faster-than-expected international volume growth and Zepbound-driven mix.